Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $177.63 Average Price Target from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYSGet Free Report) have earned an average recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $177.63.

A number of research firms recently issued reports on KRYS. HC Wainwright reiterated a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research note on Monday, May 6th. William Blair reissued an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Guggenheim raised their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Citigroup upped their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th.

Check Out Our Latest Stock Report on KRYS

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Julian S. Gangolli sold 20,000 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Institutional Trading of Krystal Biotech

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Krystal Biotech by 40.7% in the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after buying an additional 693,852 shares during the period. Jennison Associates LLC increased its stake in Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after purchasing an additional 383,495 shares during the period. First Turn Management LLC bought a new stake in Krystal Biotech in the fourth quarter valued at approximately $30,045,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Krystal Biotech by 54.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after purchasing an additional 231,255 shares during the period. Finally, Fred Alger Management LLC grew its holdings in shares of Krystal Biotech by 4,608.6% in the third quarter. Fred Alger Management LLC now owns 167,485 shares of the company’s stock worth $19,428,000 after purchasing an additional 163,928 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Up 2.1 %

Shares of NASDAQ:KRYS opened at $174.82 on Friday. The firm has a market capitalization of $4.99 billion, a PE ratio of 93.49 and a beta of 0.90. The company has a 50-day moving average price of $164.53 and a two-hundred day moving average price of $147.37. Krystal Biotech has a twelve month low of $93.95 and a twelve month high of $191.78.

Krystal Biotech (NASDAQ:KRYSGet Free Report) last released its quarterly earnings data on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. The company’s quarterly revenue was up 452400.0% compared to the same quarter last year. During the same period last year, the company earned ($1.76) EPS. Analysts anticipate that Krystal Biotech will post 2.06 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

(Get Free Report

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Recommended Stories

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.